glp-1 receptor agonists effects on cardiovascular risk reduction Impact of outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis | Clinical Research in Cardiology Glucagon-like peptide-1 receptor agonists' impact
Description
Sensitivity analyses performed with a random effects model (MHOR 1.04, 95% CI [0.97, 1.11]) and excluding openlabel trials (MHOR 1.03, 95% CI [0.95, 1.10]) provided similar results
Prespecified and post hoc analyses confirmed the consistent effects of dapagliflozin across kidney disease: improving global outcomes (KDIGO) risk categories [56,57]
Osaka T, Tsukamoto A, Koyama Y, Inoue S
6.10.6.3 Rhamnocitrin Rha has also been discovered to downregulate the TGF-1/Smads signaling pathway and to suppress NF-B through activation of PPAR- (302, 303)
For example, the LEADER trial showed that Liraglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 13% and cardiovascular death by 22% in comparison to placebo
